BeiGene Expands Presence in New Jersey with $800 Million Investment
BeiGene, a global oncology company, has established its flagship U.S. facility in Hopewell, New Jersey, aiming to bolster its...
Jon Napitupulu
ViiV Dovato: 2-Drug HIV-1 Regimen as Effective as 3-Drug Biktarvy
ViiV Healthcare’s PASO DOBLE study found that the 2-drug regimen Dovato (DTG/3TC) is as effective as the 3-drug regimen...
Azitra Strengthens Patent Portfolio with Latest Grants for Atopic Dermatitis
Azitra, Inc., a biopharmaceutical company specializing in dermatology, has secured a U.S. patent (No. 12,036,248) for its potential treatment...
Vividion Therapeutics to Expand with New Global Research and Development Center
Vividion Therapeutics expands its global reach by establishing a new research and development (R&D) center and corporate headquarters in...
Virocell Biologics Secures Master Agreement with NCI Cancer Center for Transformative Therapy
A five-year Master Services Agreement (MSA) has been signed between ViroCell Biologics and a prominent U.S. NCI-designated cancer center....
JCR Pharmaceuticals’ Innovative Gene Therapy Research Unveiled at Lysosomal Forum
JCR Pharmaceuticals unveiled significant advancements in gene therapy research at the International Forum of Lysosomal Disorders. The company’s proprietary...
Discover Hangar Ventures’ Bionic Investment
Hanger Ventures, a subsidiary of Hanger, Inc., has invested in Bionic Power, a Canadian company developing active lower-body orthotic...
Bristol Myers Squibb’s Validation for Breakthrough Cancer Treatment
Bristol Myers Squibb’s immunotherapy combination therapy, Opdivo plus Yervoy, has received validation from the European Medicines Agency (EMA) for...
Parker Institute Pledges $125M for Cancer Cure Quest
The Parker Institute for Cancer Immunotherapy (PICI) has announced a significant $125 million investment to bolster its research and...
Data Unveils Susvimo’s Enduring Power in Treating Diabetic Eye Diseases
Susvimo, an innovative refillable eye implant, has shown promising results in Phase III clinical trials for treating DME and...